Amornkeit Trading Ltd could face legal action, having been slammed by the Food and Drug Administration (FDA) for placing claims on its V1-immunitor that the product can cure HIV/AIDS.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more


FDA secretary-general Dr Wichia Chokewiwat denied that the company had been given permission to trial the drug on humans, and stressed that the product should no longer be consumed.


V1-immunitor has been registered as a food product, according to Chokewiwat. The company must now seek official registration of the product as a drug if it is to remain on the market with the health claims, a move that will enable extensive trials to take place to determine if the product actually has any value in the treatment of HIV and AIDS.


Dr Suraphong Suebwonglee, deputy Public Health Minister, commented that the company has no right to sell the product as a cure for the virus. “If they mean well [in the search for a cure for HIV/AIDS]  then they should do it in a legal way,” he said.”We’re ready to provide them with assistance.”


“The product is illegal, so the patients who are receiving, or are going to use the product, must consider on their own if it’s worth having any faith in it or not,” he added. Suraphong also stressed that the Public Health Ministry would appreciate any feedback from users on the side effects, or safety of the product in order to assess the situation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In the meantime, “if the product’s manufacturer doesn’t abandon its advertising claims that it is HIV/AIDS medicine then it will face legal action,” stressed Wichia.